Your browser doesn't support javascript.
loading
Site-specific characterization of envelope protein N-glycosylation on Sanofi Pasteur's tetravalent CYD dengue vaccine.
Dubayle, Jean; Vialle, Sandrine; Schneider, Diane; Pontvianne, Jérémy; Mantel, Nathalie; Adam, Olivier; Guy, Bruno; Talaga, Philippe.
Afiliação
  • Dubayle J; Research and Development Department, Sanofi Pasteur, Campus Mérieux, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. Electronic address: jean.dubayle@sanofipasteur.com.
  • Vialle S; Research and Development Department, Sanofi Pasteur, Campus Mérieux, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France.
  • Schneider D; Research and Development Department, Sanofi Pasteur, Campus Mérieux, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France.
  • Pontvianne J; Research and Development Department, Sanofi Pasteur, Campus Mérieux, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France.
  • Mantel N; Research and Development Department, Sanofi Pasteur, Campus Mérieux, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France.
  • Adam O; Research and Development Department, Sanofi Pasteur, Campus Mérieux, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France.
  • Guy B; Research and Development Department, Sanofi Pasteur, Campus Mérieux, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France.
  • Talaga P; Research and Development Department, Sanofi Pasteur, Campus Mérieux, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France.
Vaccine ; 33(11): 1360-8, 2015 Mar 10.
Article em En | MEDLINE | ID: mdl-25660649
ABSTRACT
Recently, several virus studies have shown that protein glycosylation play a fundamental role in the virus-host cell interaction. Glycosylation characterization of the envelope proteins in both insect and mammalian cell-derived dengue virus (DENV) has established that two potential glycosylation residues, the asparagine 67 and 153 can potentially be glycosylated. Moreover, it appears that the glycosylation of these two residues can influence dramatically the virus production and the infection spreading in either mosquito or mammalian cells. The Sanofi Pasteur tetravalent dengue vaccine (CYD) consists of four chimeric viruses produced in mammalian vero cells. As DENV, the CYDs are able to infect human monocyte-derived dendritic cells in vitro via C-type lectins cell-surface molecules. Despite the importance of this interaction, the specific glycosylation pattern of the DENV has not been clearly documented so far. In this paper, we investigated the structure of the N-linked glycans in the four CYD serotypes. Using MALDI-TOF analysis, the N-linked glycans of CYDs were found to be a mix of high-mannose, hybrid and complex glycans. Site-specific N-glycosylation analysis of CYDs using nanoLC-ESI-MS/MS demonstrates that both asparagine residues 67 and 153 are glycosylated. Predominant glycoforms at asparagine 67 are high mannose-type structures while mainly complex- and hybrid-type structures are detected at asparagine 153. In vitro studies have shown that the immunological consequences of infection by the CYD dengue viruses 1-4 versus the wild type parents are comparable in human monocyte-derived dendritic cells. Our E-protein glycan characterizations of CYD are consistent with those observations from the wild type parents and thus support in vitro studies. In addition, these data provide new insights for the role of glycans in the dengue virus-host cell interactions.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas do Envelope Viral / Vírus da Dengue / Vacinas contra Dengue Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas do Envelope Viral / Vírus da Dengue / Vacinas contra Dengue Idioma: En Ano de publicação: 2015 Tipo de documento: Article